Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan

18 Oct 2016

Abstract excerpt

The topoisomerase I (TOP1) inhibitor irinotecan triggers cell death by trapping TOP1 on DNA, generating cytotoxic protein-linked DNA breaks (PDBs). Despite its wide application in a variety of solid tumors, the mechanisms of cancer cell resistance to irinotecan remains poorly understood. Here, we generated colorectal cancer (CRC) cell models for irinotecan resistance and report that resistance is neither due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28180300
DOI: 10.1093/nar/gkw1026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecanPMID 28180300Read ↗

Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise UsSemantic proximity Read ↗

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targetsSemantic proximity Read ↗

Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to IrinotecanSemantic proximity Read ↗

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks.Semantic proximity Read ↗

New Topoisomerase I mutations are associated with resistance to camptothecin.Semantic proximity Read ↗

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal CancerSemantic proximity Read ↗

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancerSemantic proximity Read ↗

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexSemantic proximity Read ↗

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.